These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24195468)

  • 21. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
    Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
    Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.
    Yang H; Liu L; Zhou C; Xiong Y; Hu Y; Yang N; Qu J
    Medicine (Baltimore); 2019 Mar; 98(12):e14893. PubMed ID: 30896637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.
    Kunishige M; Takeuchi E
    Thorac Cancer; 2023 Dec; 14(34):3419-3420. PubMed ID: 37920971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endobronchial ultrasound-guided transbronchial needle aspiration in patients with previously treated lung cancer.
    Fujiwara T; Nakajima T; Inage T; Sata Y; Yamamoto T; Sakairi Y; Wada H; Suzuki H; Chiyo M; Yoshino I
    Surg Today; 2021 Mar; 51(3):415-421. PubMed ID: 32804303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
    Xu Y; Huang Z; Gong L; Fan Y
    Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.
    Ham JS; Kim S; Kim HK; Byeon S; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Han J; Park W; Ahn MJ
    J Thorac Oncol; 2016 Jan; 11(1):e1-4. PubMed ID: 26762749
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib.
    Yanagisawa A; Kinehara Y; Kijima R; Tanaka M; Ninomiya R; Jokoji R; Tachibana I
    Intern Med; 2023 Mar; 62(5):769-773. PubMed ID: 35871578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
    Drpa G; Sreter KB; Manojlovic S; Kukulj S
    Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidermal Growth Factor Receptor-mutated Advanced Lung Adenocarcinoma with Long-term Tumor-free Survival by Chemotherapy Followed by Tyrosine Kinase Inhibitor Treatment after Reduction Surgery].
    Morio A; Nakahara K; Futagawa T; Suzuki K
    Kyobu Geka; 2016 Dec; 69(13):1051-1054. PubMed ID: 27909271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
    J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
    Folch E; Yamaguchi N; VanderLaan PA; Kocher ON; Boucher DH; Goldstein MA; Huberman MS; Kent MS; Gangadharan SP; Costa DB; Majid A
    J Thorac Oncol; 2013 Nov; 8(11):1438-1444. PubMed ID: 24128714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.